The UK's own global health security depends on continued investment in disease research
Behind each one of the numbers is a person, a family, a community whose lives have been saved or changed for the better. We believe that as one of the richest nations in the world, the UK has an ethical responsibility to take a lead on breakthroughs in neglected diseases.
But the case for continued support and investment is much stronger than just ethical responsibility; there are widespread and measurable economic and social benefits not only in the countries where these diseases occur but in the UK itself.
A new report, by Impact Global Health in collaboration with Liverpool School of Tropical Medicine, found that the UK directly benefits from R&D investment into diseases like malaria, HIV and tuberculosis.
It shows that the UK economy would gain an additional boost of £7.7 billion and 4,000 additional jobs by 2040 from public funding of neglected disease R&D. Some £6 billion has already been gained but around £1.5 billion, equivalent to an average of £100 million a year, is yet to be felt and is contingent on funding being sustained.
And the benefits to the UK of investment in global health do not stop there.
Now is the time for bold action
Covid-19, and the West African Ebola epidemic demonstrated that infections don't recognise geographic borders. Nobody is safe from future pandemics until everybody has access to effective diagnostics, drugs and treatments and robust health systems.
Put simply: the UK's own global health security depends on continued investment in this early pipeline of global health R&D.
Yet 2025 has been a challenging year for global health – with significant cuts announced to critical funding internationally and continued uncertainty about future investment. Already, many projects have been forced to pause or stop, causing a direct negative impact on the people and communities which are most in need.
In an age where there are multiple calls on government and other budgets, global health R&D could be seen, mistakenly, as an easy target. But the impact of R&D funding in the UK and across the globe should not be underestimated.
This latest research clearly shows how this funding has already significantly improved health outcomes and positively impacted individual lives and wider society. We must keep this momentum to realise these benefits into the future.
There is a very real risk that funding cuts now or in the future will reduce the impact of what has already been achieved and will lose the opportunity to develop new products, save even more lives and create even more sustained economic benefit. Any reduction in investment could rapidly unravel the substantial progress made to date, leaving future advances in life-saving interventions in jeopardy.
Now is the time for bold action to protect critical investment in this area. Every pound of funding lost will negatively impact the UK economy, make the UK more vulnerable to future pandemics, and most importantly, expose the most vulnerable communities around the world to greater health threats.
The UK has been a leader in funding and conducting research and development targeted at neglected diseases over the last two decades. Along with saving countless lives within some of the world's poorest communities, that investment has had real health and economic benefits in the UK.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Independent
11 hours ago
- The Independent
EU regulator approves injectable HIV drug that experts say could help stop transmission
The European Medicines Agency has recommended authorizing a twice-yearly injectable drug aimed at preventing HIV, which scientists say could help end the virus' transmission. In a statement on Friday, the EU drug regulator said its evaluations of lenacapavir, sold as Yeytuo in Europe by Gilead Sciences, showed the drug is 'highly effective' and 'considered to be of major public health interest.' Once the regulator's guidance is accepted by the European Commission, the authorization is valid in all 27 EU member countries as well as Iceland, Norway and Liechtenstein. Last year, studies suggested that lenacapavir, already used to treat people with HIV, was nearly 100% effective in stopping transmission in both women and men. Winnie Byanyima, executive director of the U.N. AIDS agency, has said the drug 'could change the trajectory of the HIV epidemic' if it is made available to everyone who needs it. In June, the U.S. Food and Drug Administration authorized lenacapavir to prevent HIV. Earlier this month, the World Health Organization recommended countries offer the drug as an additional option to people at risk of the virus. Condoms help guard against HIV infection if used properly. Other medication aimed at preventing HIV include daily pills that people can take and another injectable drug called cabotegravir, which is given every two months. Lenacapavir's six-month protection makes it the longest-lasting type, an option that could attract people wary of more visits to health clinics or stigma from taking daily pills. Critics have raised concerns, however, that lenacapavir may not be made widely enough available to stop global outbreaks of HIV. Drugmaker Gilead has said it will allow cheap, generic versions to be sold in 120 poor countries with high HIV rates — mostly in Africa, Southeast Asia and the Caribbean. But it has excluded nearly all of Latin America, where rates are far lower but increasing, sparking concern the world is missing a critical opportunity to stop the disease. Last year, there were about 630,000 AIDS deaths worldwide and more than 40 million people are estimated to have HIV, according to UNAIDS. UNAIDS chief Byanyima has previously suggested the U.S. President Donald Trump make a deal with Gilead to produce and license its 'magical' prevention drug lenacapavir across the world to the millions of people who need it. ___ The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
Reuters
11 hours ago
- Reuters
Breakingviews - GSK revenue hole raises chances of risky M&A move
DUBLIN, July 25 (Reuters Breakingviews) - Emma Walmsley, the boss of 57-billion-pound ($77 billion) GSK (GSK.L), opens new tab, has a conspicuously large financial target: generating over 40 billion pounds of revenue by 2031, opens new tab. Right now, she's well behind pace. Given the drugmaker's track record of buying growth, M&A seems like a likely option to make up for lost time. Shareholders will have to be on the lookout for GSK potentially overpaying. Since Walmsley took the helm of the maker of vaccines and HIV treatments in 2017, opens new tab, the company's forward earnings multiple has collapsed from over 12 to less than eight. Spinning off consumer-focused unit Haleon (HLN.L), opens new tab in 2022, opens new tab has only shone a light on the core pharmaceutical group's problems. Analysts currently reckon GSK will rake in just 34 billion pounds of revenue in 2031, according to forecasts gathered by Visible Alpha, which is 15% less than Walmsley's minimum ambition. One reason is that vaccines, which made up nearly a third of sales in 2024, are potentially under threat from U.S. Health Secretary Robert F. Kennedy Jr., a longtime sceptic of immunisations. Another concern is that Dolutegravir, GSK's star HIV treatment which produced nearly 20% of the company's 31 billion pounds of revenue last year, will lose some patent protection from 2028 in the key U.S. market. Walmsley has claimed that she can replenish the shortfall with future sales from many of the company's 14, opens new tab promising drugs under development. But despite GSK delivering 13 positive late-stage drug trials last year, investors seem more focused on the disappointments. Last week, the group's shares fell nearly 5% after its blood cancer medication Blenrep faced a regulatory setback on safety concerns in the U.S. That all explains the appeal of M&A. Since spinning off Haleon, Walmsley has committed over 6 billion pounds to companies that specialise in everything from vaccines to treatments for cancer, lung and liver disorders. She has more firepower. The company will end 2025 with 12.9 billion pounds of net debt, analysts reckon, which is not much more than the average forecast for 11 billion pounds of EBITDA this year, based on estimates collated by Visible Alpha. One common rule of thumb is that public-market investors only start getting antsy when leverage approaches 3 times EBITDA, implying that Walmsley has 20 billion pounds of headroom for M&A. There are several possible targets. GSK could buy out the 89% of $1.3-billion Wave Life Sciences (WVE.O), opens new tab that it doesn't already own. Another option might be $4 billion obesity drug-focused biotech Viking Therapeutics (VKTX.O), opens new tab, which could bring a foothold in a red-hot market. The risk, however, is that any sellers see GSK as a desperate bidder, leading to a higher asking price. Paying over the odds simply to fill a revenue hole would destroy shareholder value, but it wouldn't be unprecedented in the pharma sector. In GSK's case, it would make an already unhealthy valuation even sicklier. Walmsley's investors will be on high alert. Follow Aimee Donnellan on LinkedIn, opens new tab.
The Guardian
13 hours ago
- The Guardian
The Gaza students with scholarships to UK unable to take up their places
Time is running out for 40 students in Gaza who have been awarded full scholarships to study at some of the UK's leading universities this September, but have been unable to fulfil visa requirements due to the war. Campaigners have called on the British government to intervene to ensure their safe passage. Here are some of the students' stories. Abdallah, 27, has been awarded a Chevening scholarship, part of a UK government-funded global scholarship programme, and has a place to study for an MSc in data science and artificial intelligence (AI) at Queen Mary University of London. 'Just two weeks after earning my medical licence in 2023, the war broke out. I chose not to flee. Instead, I volunteered in local hospitals, treating the wounded while my own family suffered nearby. 'I soon realised that bandages and medicine cannot heal a nation so deeply traumatised. We need more than emergency care – we need innovation. That is why I applied to study data science and AI in the UK. 'I am driven by desperation and hope. Gaza is facing an unprecedented mental health catastrophe. Nearly every child and adult has been exposed to intense trauma, displacement, or loss. Yet Gaza's mental health infrastructure has been completely shattered. 'To fight a crisis this massive, I need world-class training. Once I complete my degree, I will return to Gaza to lead the creation of data-driven health systems that prioritise mental wellbeing.' Israa, 31, is a Palestinian doctor who has been awarded a Medical Research Council doctoral training partnership to do a PhD in sexual and reproductive health at the Liverpool School of Tropical Medicine, where she previously completed a master's in international public health. She said: '[Studying in the UK was] a transformative experience that gave me a global perspective and strengthened my resolve to serve the most vulnerable people. I returned to Gaza by choice to serve, to heal and to uplift. A few months later, the brutal war started. 'I now work supporting women, girls, adolescents and displaced communities. I was supposed to start my [PhD] studies in October 2024, but the award was deferred to this October. I am calling for immediate action to evacuate UK scholars and professionals from Gaza, not only for my safety, but for the future I represent. 'My work, my voice, and my life matter. I am not only a doctor or a student, but I am also a survivor, a woman, a wife, and a human being who has dedicated her life to health equity and justice.' Israa added: 'It is not easy to guarantee we will be alive next week. The more we accelerate the efforts [to evacuate the students] the better for us.' Khulud, 28, is another Chevening scholar with a place at University College London to study for a master's degree in dental health. After completing her dental degree at the University of Palestine in 2020, she worked in clinical dentistry while training others. When the war began, Khulud opened a clinic with her brother, offering free dentistry, general medicine, paediatrics, nutrition, and psycho-social care to over 20,000 displaced people. 'These experiences didn't just shape me – they saved me,' she said. 'Even in the darkest moments, there is light in service, and hope in community. 'The situation in Gaza is catastrophic. There are continuous attacks, mass displacement, and severe shortages of food and medical supplies. Thousands have died, and many more are at risk. I cannot say with certainty that I'll still be alive in 2026. 'Losing this scholarship and the resources I've secured would be devastating. Emotionally, it would extinguish one of the few hopes that keep me resilient. Academically, the programme might not be available again. Most importantly, it would deny Gaza a health professional determined to return and help rebuild.' Majd, 24, a mechanical engineer from Gaza, has a full scholarship to pursue a master's degree in advanced manufacturing systems and technology at the University of Liverpool. He said: 'Life during the war has been extremely difficult. I've been displaced, with no stable electricity, internet, or basic services. Every day is full of uncertainty and worry. 'Most industrial facilities in Gaza have been destroyed, which means there's almost no equipment or resources left to work with. The lack of electricity, fuel, and basic infrastructure has made it nearly impossible to continue any kind of engineering work. 'The UK offers world-class education with excellent research and teaching. Studying there will give me access to resources that will improve my knowledge in advanced technologies. This international experience is vital for me to develop the skills needed to contribute meaningfully to Gaza's future reconstruction. 'I want to use what I learn to create job opportunities, empower youth, and help rebuild infrastructure that supports long-term stability and growth in Gaza after the war. 'I fully understand that the UK has visa systems in place for important reasons, and we are not asking for special treatment. However, this is an extraordinary situation. We ask for consideration and support to enable us to continue our studies, as education will be key to rebuilding Gaza.' Abeer, 28, has a place to study for an MA in data and health science at the University of St Andrews. 'After our home was destroyed in the winter of 2023 we moved into an Unrwa school. After three days there the school was heavily shelled. 'The bombing was violent and horrific. My brother Mohamed was badly injured, his feet caught underneath the falling rubble. He could not walk or move. We had to carry him south to Khan Younis, where we lived in a tent. 'It was here that we lost Mohamed. He never recovered from the injury at the Unrwa school. His loss caused our whole family to collapse. I felt my heart had stopped pumping. I lost my will to live, life lost its meaning. 'It was not long after that my older brother reached out, and reminded me that I had wanted to apply for a scholarship at St Andrews. 'Hardship should not stop you,' he told me. 'This is what you wanted before, you must persist.' 'Coming from Gaza I have seen the need for better health care solutions, and this programme and its modules offer the knowledge I need to make a real impact on health care.' Samah, 25, a medical laboratory specialist at al-Ahli Arab hospital in Gaza, has been accepted to study for an MSc in genomic medicine at the University of Oxford. She did not wish to share any photos of herself. 'From the first day of the ongoing war in Gaza, I have been on the frontline, working under extremely difficult and life-threatening conditions. Our hospital, like many others, faced mass casualties on a daily basis. We lost most of our laboratory equipment due to targeted attacks and destruction, yet we continued to serve patients. 'As the war progressed, I witnessed families resorting to burning hazardous materials just to cook food for their children. This prolonged exposure to potentially carcinogenic agents made me realise the urgent need to understand the long-term biological and genetic impacts of such conditions. 'Motivated by this experience, I decided to pursue advanced study in the field of medical genetics and cancer research. 'This opportunity is not just an academic pursuit for me, it is a mission to bring hope and healing back to a devastated community.' These accounts were compiled with the help of the UK Coalition for Students in Gaza
